Expertise in
34
conditions

Dr. Perminder J. Bhatia

Neurology
Fresno Community Hospital And Medical Center
2823 Fresno St, 
Fresno, CA 
Expertise in
34
conditions
Fresno Community Hospital And Medical Center
2823 Fresno St, 
Fresno, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Perminder Bhatia is a Neurologist in Fresno, California. Dr. Bhatia is highly rated in 34 conditions, according to our data. His top areas of expertise are Seizures, Memory Loss, Autosomal Dominant Partial Epilepsy with Auditory Features, and Movement Disorders.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Hospital Affiliations
Community Regional Medical Center
Clovis Community Medical Center
Kaweah Health Medical Center
Languages Spoken
English
Punjabi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

FRESNO COMMUNITY HOSPITAL AND MEDICAL CENTER
2823 Fresno St, Fresno, CA 93721

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Enrollment Status: Active_not_recruiting
Publish Date: September 20, 2024
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: YKP3089
Study Phase: Phase 3
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
Enrollment Status: Withdrawn
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
Enrollment Status: Completed
Publish Date: February 14, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Enrollment Status: Terminated
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 12 Less Clinical Trials

5 Total Publications

Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Journal: Brain : a journal of neurology
Published: December 12, 2023
Similar Doctors
Expertise in
8
conditions
Dr. Ernestina H. Saxton
Neurology
Expertise in
8
conditions
Dr. Ernestina H. Saxton
Neurology
2335 E Kashian Ln, Suite 301, 
Fresno, CA 
 (0.1 mi)
559-264-9100
Languages Spoken:
English

Ernestina Saxton is a Neurologist in Fresno, California. Dr. Saxton is highly rated in 8 conditions, according to our data. Her top areas of expertise are Thoracic Outlet Syndrome, Syringomyelia, Migraine, and Chiari Malformation Type 2.

Expertise in
34
conditions
Dr. Harrol T. Hutchison
Neurology | Medical Genetics | Pediatrics
Expertise in
34
conditions
Dr. Harrol T. Hutchison
Neurology | Medical Genetics | Pediatrics
2335 E Kashian Ln Ste 301, 
Fresno, CA 
 (0.5 mi)
559-264-9100
Languages Spoken:
English
See accepted insurances

Harrol Hutchison is a Neurologist and a Medical Genetics provider in Fresno, California. Dr. Hutchison is highly rated in 34 conditions, according to our data. His top areas of expertise are Myotonic Dystrophy, Myotonic Dystrophy Type 2, Paramyotonia Congenita, and Myasthenia Gravis.

Expertise in
8
conditions
Dr. Hana M. Choe
Neurology
Expertise in
8
conditions
Dr. Hana M. Choe
Neurology

Community Health Partners

7257 N Fresno St, 
Fresno, CA 
 (6.9 mi)
559-451-3687
Languages Spoken:
English
See accepted insurances

Hana Choe is a Neurologist in Fresno, California. Dr. Choe is highly rated in 8 conditions, according to our data. Her top areas of expertise are Stroke, Apoplexy, Subarachnoid Hemorrhage, Thrombectomy, and Stent Placement.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhatia's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile